



Eugen Münch
Chairman of the Supervisory Board

REPORT OF THE SUPERVISORY BOARD

FOR THE FINANCIAL YEAR OF RHÖN-KLINIKUM AG
FROM 1 JANUARY 2013 TO 31 DECEMBER 2013

DEAR SHAREHOLDERS,

The year 2013 marks a milestone and fork-in-the-road in the more than 40-year history of RHÖN-KLINIKUM. It is a milestone because in the autumn of 2013 the resolution was adopted to bring a large portion of the Company into the Fresenius Group ("Project Scala"). It is a fork-in-the-road because this means not only an end to RHÖN-KLINIKUM as hitherto known, but also the start of a new journey: the contribution of most of our hospitals and sites to the Fresenius subsidiary Helios Kliniken has created the foundation for establishing and expanding network medicine and thus shaping the sector and the market more along the lines of self-determination. This step was and is vital to the companies' future. It is the outcome of demographic trends, advances in medicine and the cost gap arising from the failure to carry through with reforms under the existing system. There is no other way to resolve rising performance pressures from growing patient numbers and price restrictions imposed by legislation.

As always, phases of change and transformation meet with resistance, fear of change and insecurity, but are nonetheless indispensable. Undeterred by these obstacles, the Supervisory Board and the Board of Management can look back on positive and successful co-operation in a difficult environment.

CO-OPERATION BETWEEN BOARD OF MANAGEMENT AND SUPERVISORY BOARD

During financial year 2013, the Supervisory Board examined on an ongoing basis and in detail the situation and development of our Company, performing the duties incumbent on it by law and the Articles of Association: these notably include monitoring the management activity of the Board of Management and advising the Board of Management on the operative management of the Company. At the same time the Supervisory Board, in performing its duties, was at all times guided by the decisive principles of appropriateness, compliance with legal provisions, expediency and efficiency. Observance of these principles by the Board of Management was monitored by regularly reviewing the Company's general organisation and verifying the instruments used for internal risk control.

The Supervisory Board was fully and directly involved in all fundamental and important decisions of the Board of Management of RHÖN-KLINIKUM AG. The Board of Management kept us informed on a timely basis both in written form and orally, with documents and records of relevance for decisions being provided to the Supervisory Board in good time prior to the respective deliberations and formal meetings. The Supervisory Board reviewed the information submitted by the Board of Management regarding operative business performance, compliance issues as well as risks and risk management in terms of conclusiveness and plausibility and also scrutinised the same whenever required.

The focus of the consultations was on the implications and lessons from the hitherto unsuccessful attempts to forge a merger with Helios Kliniken as well as on the restructuring and sustained economic recovery of Germany's first private university hospital, Universitätsklinikum Gießen und Marburg GmbH. A further focus of interest of the exchange with the Board of Management was on the integration of the Wiesbaden-based hospital company Dr. Horst Schmidt Kliniken GmbH and its subsidiaries acquired in financial year 2012, as well as on the personnel changes within the Board of Management. The chairman of the Supervisory Board was moreover kept informed – also between the scheduled meetings of the Supervisory Board and its committees – on a continuous basis and thoroughly by the chairman of the Board of Management. We have not found the Board of Management to have breached any of its duties to inform. We thoroughly discussed the resolution proposals of the Board of Management and, to the extent required by statute and the Articles of Association, gave our vote on the same after a thoroughgoing review – in isolated cases seeing the need to consult external experts and advisers in the interests of the shareholders. Where required in the case of particularly pressing business matters, the Supervisory Board or, as the case may be, the competent committee held conference calls and adopted resolutions by voting in written form.

WORK OF THE SUPERVISORY BOARD IN COMMITTEES AND PLENARY MEETING

With a view to performing its tasks and assuming its responsibility in the best possible way, the Supervisory Board has set up a total of seven standing committees whose members possess specific expertise and experience for the special issues dealt within the committees.

The committees act as bodies with power to pass resolutions within the scope prescribed by law, the Articles of Association – also in lieu of the Supervisory Board – and the Terms of Reference of the latter to the extent consistent with statute and previously defined by the Supervisory Board. The committees generally meet separately from plenary meetings. However, wherever required by the subjects to be covered, joint meetings of committees were also held drawing on the expertise of the respective committees. In addition, conference calls were held as required at short notice.

The **Investment, Strategy and Finance Committee** held six ordinary meetings during the year under review (attendance rate: 96 per cent), of which one meeting was held as a joint meeting with the Audit Committee.

One of the areas focused on in the strategic consultations within the Committee was the further development and implementation of a business model for creating full-service generalised healthcare provision with national coverage including supplementary insurance for members of Germany's statutory health insurance scheme by creating a network with a broad, generalised presence. The realisation of this concept can be likened to the transformation of a heavily dependent supplier into a brand-oriented retail player. To further escort this project, we formed a "Network Medicine" working group from members of the Investment, Strategy and Finance Committee, the Board of Management and specialist advisers which met five times during the financial year.

At all meetings, the Committee examined the economic development of the subsidiary Universitätsklinikum Gießen und Marburg GmbH, in particular the options for measures and actions to improve earnings as a result of the analysis performed by the corporate consultancy firm McKinsey as well as the implementation of the "Joint Agreement relating to medical care provision in Central Hesse, securing research and teaching at Gießen and Marburg University Hospitals and improving job security" entered into between the Federal State of Hesse, RHÖN-KLINIKUM AG, Universitätsklinikum Gießen und Marburg GmbH, Justus-Liebig University Gießen and Philipps University Marburg. This also included deliberations on developing a concept for operating the particle therapy centre in Marburg.

The Committee thoroughly examined the execution and consequences of the Share Purchase and Transfer Agreement relating to the sale of 43 hospital companies and 15 medical care centres (MVZs) entered into on 13 September 2013 with Fresenius / Helios and the resulting impact on the Company's structure and further development.

In addition to the report of the chairman of the Board of Management on current developments, the Board of Management routinely remitted an acquisitions report which, along with providing an overview of the national hospital market, also served as the basis of discussion for planned and ongoing acquisition projects. The investment plan for financial year 2013 was approved after being discussed critically and in terms of content. Measures developed by the Board of Management to improve efficiency and financing, such as the earnings improvement programme "ImPULS", were presented and discussed in detail within the Committee.

REPORT OF THE
SUPERVISORY BOARD

At all meetings the Board of Management moreover reported on the development of investments and financing in a continuously updated investment and finance plan. Specific motions for approval of investment projects on debt capital measures in the context of refinancing were subsequently openly discussed, critically reviewed and adopted based on detailed written resolution proposals of the Board of Management, including market studies, investment calculations and finance offers.

The joint meeting with the Audit Committee towards the end of the financial year dealt with the thoroughgoing discussion regarding the stage of development of the merger of numerous RHÖN hospitals with Helios hospitals, the possible impact of a delayed approval by the Federal Cartel Office resulting from the initiation of a main examination proceeding, and the discussion regarding the options for using the sale proceeds and disbursing the liquidity not needed to the shareholders. This meeting also dealt with the further actions needed to implement the "Joint Agreement" with the Federal State of Hesse giving due regard to the situation brought about by the elections in Hesse and the reorganisation of the RHÖN-KLINIKUM Group.

During the reporting year, the **Personnel Affairs Committee** held one meeting (attendance rate: 75 per cent). The Committee looked at the current remuneration situation of the members of the Board of Management and the impact of declining earnings on the performance-linked remuneration components. As a result of the consultations, a consensus was reached that a resolution proposal aimed at modifying the remuneration guidelines to introduce a minimum remuneration (guaranteed total annual remuneration) and at the same time a cap on such total annual remuneration should be made to the plenary meeting of the Supervisory Board. Additional resolution proposals to amend the existing service agreements of the Board of Management were made for the purpose of including a minimum threshold for total remuneration and a cap as regulated in the remuneration guidelines as well as amendments to company car provisions.

The Committee furthermore dealt with the appraisal of the performance and development of the individual members of the Board of Management and of the Board of Management as a whole. In this connection, the expectations of the members of the Board of Management and their prospects for further development within the Company were also discussed.

During the past financial year, the **Mediation Committee** (pursuant to section 27 (3) of the Co-Determination Act (Mitbestimmungsgesetz, MitBestG)) also did not have to be convened.

The **Audit Committee** of the Supervisory Board met six times in the year under review (attendance rate: 100 per cent). All meetings were attended by all members of the Board of Management. Two meetings were attended by the statutory auditor. For selected agenda items, the heads of the Internal Auditing and Compliance departments were consulted by the Board of Management, and were available to the Committee for additional reports and questions. At one meeting towards the end of the financial year, issues involving different fields in connection with Project Scala and Universitätsklinikum Gießen und Marburg GmbH were discussed together with the Investment, Strategy and Finance Committee.

This Committee was notably responsible for reviewing and preparing the RHÖN-KLINIKUM AG consolidated annual financial statements for financial year 2012. Also reviewed and discussed were the stand-alone financial statements, the management reports and the respective audit reports of the Group subsidiaries (here with particular emphasis on the annual financial statement of Universitätsklinikum Gießen und Marburg GmbH) which were subjected to critical review by the members of the Committee, as well as the proposal on the appropriation of the net distributable profit.

The Audit Committee assessed the independence of the auditor designated for auditing the annual financial statements for financial year 2013 and for the review of the Half-Year Financial Report, obtained the statement regarding the auditor's independence pursuant to Item 7.2.1 of the German Corporate Governance Code, recommended to the plenary meeting of the Supervisory Board a proposal for the election of the auditor to be submitted to the Annual General Meeting and – after the election – issued the auditor with the audit mandate and concluded with him a reasonable remuneration agreement for the same. The statutory auditor moreover reported to the Committee on orders for services performed in addition to the auditing services rendered. The qualification of the statutory auditor was monitored by the Committee. A list of audit items was developed and defined for the audit in 2013.

Questions of fundamental importance relating to accounting, corporate planning, the capital base, the supervision of the accounting process, as well as the effectiveness of the internal controlling system, risk management system (including special business risks), the internal audit system and the compliance system were discussed with the Board of Management and in some cases also with the statutory auditor. The interim reports were thoroughly discussed on a regular basis with the Board of Management prior to their publication as well as the half-year financial report with the Board of Management and the statutory auditor. Here, special emphasis was placed on analysing the causes for the declining trend in earnings of the current financial year.

The Group controlling report on performance and finance controlling submitted quarterly, which forms part of our risk management system, was thoroughly discussed with the Board of Management. Here the performance trend of the Group's individual hospitals is presented, discussed and scrutinised by the Board of Management both at the hospital level and at the level of the specialist department.

The body kept itself regularly informed about the activity of the Internal Auditing department by the responsible member of the Board of Management and by reports submitted by the head of Internal Auditing who attended four meetings, and examined the auditing plan for financial year 2013 as well as its update. The audit reports of the Internal Auditing department as well as the 2012 activity report were then submitted and discussed with the Board of Management. We kept ourselves informed by the Board of Management on the implementation of the recommendations by the Internal Auditing Department through information on the results of follow-up reporting and inspection.

The Board of Management regularly reported to us on the organisation and work of the Compliance department, with the result that we were once again convinced of the effectiveness of our compliance management system. The head of the Compliance department attended four meetings of the Audit Committee. The audit reports of the Compliance department as well as the 2012 activity report were then submitted and discussed with the Board of Management. The Audit Committee approved the compliance programme for 2013. Regular reporting by the Board of Management in this regard also includes a quarterly report on notified violations, their investigation and eradication. At each meeting the Board of Management moreover informed about the stage reached in a customs investigation proceeding concerning the Group's cleaning companies – initiated already at the end of 2011 but not yet concluded – for suspicion of withholding remuneration for work.

In updating the Declaration of Compliance pursuant to section 161 of the German Stock Corporation Act (Aktiengesetz, AktG) relating to the recommendations of the German Corporate Governance Code, the version of 13 May 2013 was reviewed as to its application and duly reflected, with a corresponding resolution proposal being submitted to the Supervisory Board as a whole.

REPORT OF THE
SUPERVISORY BOARD

The **Anti-Corruption Committee** is the point of contact for employees, suppliers and patients in suspected cases of corruption. During the past financial year, no employee, supplier or patient turned to the Committee to notify a suspected case of corruption. For this reason, no meetings of the Committee were necessary. The reports of the Auditing and Compliance department to the Audit Committee confirm the impression that parties are still increasingly turning in most cases to the compliance officers of the hospitals. That is a good sign of a functioning compliance management system. The previous Anti-Corruption Committee was dissolved at the meeting of 6 November 2013. At the same meeting, a new committee, the **Committee for Compliance and Communication**, was established to assume the task of compliance management for the Group as well as communication with the media and capital markets. Compliance control, which had hitherto been covered by the Audit Committee, was transferred to this new committee. To ensure a close link to the Audit Committee, the chairman of the Committee for Compliance and Communication was assigned a seat on the Audit Committee.

The **Medical Innovation and Quality Committee** monitors the situation and development of medical quality in the Company. During the financial year the Committee held one meeting (attendance rate: 100 per cent). The meeting dealt with the discussion of the prerequisites for putting into service the particle therapy facility in Marburg as well as subjects of quality development within the Group.

The **Nomination Committee** selects candidates from the shareholders' representatives to be members of the Supervisory Board and proposes them to the Supervisory Board for nomination. At its meeting on 24 April 2013, the Committee approved the nomination of Dr. Heinz Korte for the Supervisory Board election to be held at the Annual General Meeting on 12 June 2013. The motion by the chairman of the Supervisory Board for judicial appointment of Mr. Stephan Holzinger as a substitute member to succeed the resigned Supervisory Board member Professor Dr. Dr. Karl Lauterbach was approved by the Committee by written procedure. The motion by the Board of Management for judicial appointment of Dr. Katrin Vernau and Mr. Reinhard Hartl as substitute members to succeed the resigned Supervisory Board members Mr. Caspar von Hauenschild and Dr. Rüdiger Merz was approved by unanimous resolution of the eight shareholders' representatives.

During the reporting year, a total of seven meetings were held by the **plenary** Supervisory Board, of which there were four ordinary meetings (attendance rate: 92 per cent) and three extraordinary meetings (attendance rate: 90 per cent). One member was unable to attend any of the plenary meetings due to illness. Of the remaining members of the Supervisory Board, no member attended fewer than half the meetings.

At the extraordinary meeting of the Supervisory Board on 25 March 2013, the body primarily dealt with the terms and possible consequences of implementing the Joint Agreement regarding Universitätsklinikum Gießen und Marburg GmbH entered into with the Federal State of Hesse. In two further extraordinary meetings on 6 September 2013 and on 12 September 2013, the consultations revolved around the sale of an equity portfolio of hospitals, service companies and medical care centres (MVZs) to the Fresenius / Helios Group (Project Scala) as well as the conclusion of a network agreement with Helios. In the presence of the Supervisory Board's legal adviser, the contemplated transaction was thoroughly and critically discussed based on the extensive documentation (draft contracts, expertises, expert opinions, business plan). After examining the arguments brought by the members and careful consideration, the Supervisory Board approved the sale of the equity portfolio to the Fresenius / Helios Group and the conclusion of the network agreement by majority resolution on 12 September 2013.

At the four ordinary meetings of the Supervisory Board the plenary meeting, based on detailed written reports and presentations by the Board of Management, regularly deliberated together with the Board of Management on the net assets, financial position and results of operations, the trend in revenues and earnings, the performance data, key ratios and personnel of the Company and Group as well as of the individual Group subsidiaries. The respective interim reports for the past quarters were explained by the Board of Management in detail at the plenary meeting prior to publication. At each meeting, information was regularly provided on the stage of implementation of the Joint Agreement with the Federal State of Hesse with regard to Universitätsklinikum Gießen und Marburg GmbH as well as the respective stage reached in the investigation proceeding against the service companies.

At the meeting on 20 February 2013 the Supervisory Board, on the recommendation of the Personnel Affairs Committee, adopted resolutions on the amendment of the remuneration guidelines of the members of the Board of Management and the conclusion of agreements amending service agreements of the Board of Management. The report by the Board of Management on the preliminary 2012 annual financial statements was received and the dividend proposal for financial year 2012 was approved.

At the balance sheet meeting on 24 April 2013 which was also attended by the statutory auditors, the plenary meeting discussed the annual financial statements and management report of RHÖN-KLINIKUM AG as well as the consolidated financial statements and the Group management report for financial year 2012 together with the Board of Management and the statutory auditor. The auditors reported on the essential findings and results of the audits and were available to the Supervisory Board for questions and additional information. The plenary meeting approved the annual financial statements. Also discussed at this meeting were the preparations for the 2013 Annual General Meeting, in particular the adoption of resolution recommendations of the Supervisory Board on the resolution proposals in the agenda items for the Annual General Meeting after a prior discussion of the agenda items. Approval resolutions were also adopted for the Report of the Supervisory Board, Corporate Governance Report and the Declaration on Corporate Governance pursuant to section 289a of the German Commercial Code (Handelsgesetzbuch, HGB).

The meeting on 3 July 2013, in addition to addressing routine subjects, reported on and examined in detail the earnings improvement programme ImpULS developed by the Board of Management and comprising the elements of medical and network strategy and optimisation concepts in the medical and non-medical area. Counteractions were discussed and preparatory measures taken in response to the avoidance actions announced following the Annual General Meeting with regard to the resolutions adopted there.

Based on the report from the Personnel Affairs Committee, the plenary Supervisory Board meeting on 6 November 2013 looked at remuneration matters and adopted the resolutions required for this. The Anti-Corruption Committee was dissolved by way of resolution because its scope of responsibilities had been altered by the functioning compliance management system. The composition of the newly established Committee for Compliance and Communication is to be based on the principle of equal representation. The Terms of Reference of the Supervisory Board were revised and the amended version adopted. An additional resolution was adopted on the performance of an external efficiency audit of the Supervisory Board's work and the determination of the moderator. Proposals for the appropriation of the 2013 net distributable profit and the possibilities of disbursing a portion of the purchase price from the Fresenius / Helios transaction were revealed and critically debated. There was agreement that a share buy-back involving cancellation of the shares for part of the registered share capital in a simplified cancellation procedure should take place; a distribution exclusively via special dividend was rejected.

CORPORATE GOVERNANCE CODE AND DECLARATION OF COMPLIANCE

During the past financial year, the Supervisory Board also examined the further development and implementation of the recommendations and suggestions as set out in the German Corporate Governance Code. The Declaration of Compliance issued on 7 November 2012 pursuant to section 161 of the Stock Corporation Act (AktG) was revised on 24 April 2013 and, giving due regard to the revision of the Code on 13 May 2013, was replaced by an updated Declaration of Compliance issued on 6 November 2013 by the Board of Management and the Supervisory Board. The declarations were permanently made available to the shareholders on the Company's website. In accordance with Item 3.10 of the German Corporate Governance Code, the Board of Management and the Supervisory Board jointly report on corporate governance on pages 26 to 39 of this Annual Report.

EXAMINATION AND APPROVAL OF THE 2013 FINANCIAL STATEMENTS

The Board of Management adopted the financial statements of the Company and the management report for the year ended 31 December 2013 in accordance with the provisions of the German Commercial Code (HGB), while the consolidated financial statements and Group management report for the year ended 31 December 2013 were adopted pursuant to section 315a of the German Commercial Code (HGB) in accordance with the principles set out in the International Financial Reporting Standards (IFRS). The auditors, PricewaterhouseCoopers Deutsche Revision Aktiengesellschaft Wirtschaftsprüfungsgesellschaft, Frankfurt am Main, have examined the financial statements of the Company and management report as well as the consolidated financial statements and group management report for the year ended 31 December 2013. The auditors of the accounts issued an unqualified auditor's report in each case.

The financial statements of the Company and management report, the consolidated financial statements and Group management report as well as the reports of the auditors on the result of their audit were received by all members of the Supervisory Board together with the Management's proposal for the appropriation of the net distributable profit for the year. These documents were examined by the Supervisory Board and thoroughly discussed by the Audit Committee and Supervisory Board with representatives of the auditors at the respective balance sheet meetings. As part of the audit, the Audit Committee and the Supervisory Board examined both the accounting findings and the procedures and processes relating to the accounting findings. As the standard of their review, they primarily applied the criterion of legality and verified whether the documents submitted comply with legislation in force and in particular with applicable accounting rules. Furthermore, in addition to their review of legality they also conducted an expediency review in terms of accounting, financial and business policy aspects. Based on the findings of the preliminary review by the Audit Committee, the Supervisory Board concurred with the findings of the auditors and, having conducted its own review, determined that it sees no grounds for objections.

The Supervisory Board approved the financial statements of the Company and the consolidated financial statements prepared by the Board of Management at the meeting on 29 April 2014 on recommendation of the Audit Committee; the financial statements of the Company are thus adopted as final. The proposal of the Board of Management on the appropriation of net distributable profit which increased as a result of the successful Fresenius / Helios transaction was reviewed in particular with regard to the economic position, liquidity situation and in view of the funds required for restructuring the Company as well as giving due regard to the justified interests of the shareholders. The Supervisory Board approves the Board of Management's proposals for the appropriation of net distributable profit.

CHANGES AND COMPOSITION OF THE BOARD OF MANAGEMENT

This Annual Report presents the composition of the Board of Management and the personal data, functions and duties of the individual members of the Board of Management under the heading "Corporate bodies of the Company".

The Board of Management was composed of four members at the beginning of the financial year. With effect from 1 January 2013, Dr. Dr. Martin Siebert was appointed as chairman of the Board of Management and Mr. Jens-Peter Neumann as his permanent representative. Mr. Volker Feldkamp resigned his office as of 9 August 2013 for personal reasons and left the Company. The operative and specialist responsibilities are being performed by the remaining members of the Board of Management. The Supervisory Board thanks Mr. Feldkamp for the successful work he carried out over the past years.

CHANGES WITHIN THE SUPERVISORY BOARD

Dr. Heinz Korte, retired notary public and attorney, Ammerland, after expiry of the term of his judicial appointment, was elected as a member of the Supervisory Board by the Annual General Meeting on 12 June 2013. Professor Dr. Dr. Karl Lauterbach resigned from his office as of 4 June 2013. As his successor, Mr. Stephan Holzinger, management consultant, Lenggries, was appointed as a member of the Supervisory Board until the next Annual General Meeting upon announcement of the decision by the Local Court of Schweinfurt of 3 July 2013. With effect from 12 September 2013, Mr. Caspar von Hauenschild and Dr. Rüdiger Merz resigned their office. Upon announcement of the decision by the Local Court of Schweinfurt of 19 and 20 December 2013, Mr. Reinhard Hartl, auditor and tax advisor, Icking/Irschenhausen, and Dr. Katrin Vernau, Dean of the Roland Berger School of Strategy and Economics, Hamburg, were appointed as members of the Supervisory Board until the next Annual General Meeting upon the motion by the Board of Management.

The organisational structure of the Supervisory Board and the composition of the committees during the past financial year and at the present time are set out in the overview provided following this Report.

Bad Neustadt a. d. Saale 29 April 2014

The Supervisory Board

Eugen Münch
Chairman

OVERVIEW OF
ORGANISATIONAL STRUCTURE

OVERVIEW OF THE ORGANISATIONAL STRUCTURE OF THE SUPERVISORY BOARD AND COMPOSITION OF THE STANDING COMMITTEES

CHAIR OF THE SUPERVISORY BOARD

Chairman
Eugen Münch

1st Deputy Chairman
Joachim Lüddecke

2nd Deputy Chairman
Wolfgang Mündel

COMPOSITION OF THE COMMITTEES

INVESTMENT, STRATEGY AND FINANCE COMMITTEE

Eugen Münch
Chairman
Peter Berghöfer
Klaus Hanschur
(from 17 April 2014)
Stefan Härtel
Detlef Klimpe
Dr. Heinz Korte
Joachim Lüddecke
Michael Mendel
Wolfgang Mündel
Werner Prange
(until 27 February 2014)

PERSONNEL AFFAIRS COMMITTEE

Eugen Münch
Chairman
Stefan Härtel
(from 12 March 2014)
Joachim Lüddecke
Dr. Brigitte Mohn
Annett Müller
(until 27 February 2014)

MEDIATION COMMITTEE

Eugen Münch
Chairman
Sylvia Bühler
Detlef Klimpe
Joachim Lüddecke

AUDIT COMMITTEE

Wolfgang Mündel
Chairman
Sylvia Bühler
(until 3 July 2013)
Reinhard Hartl
(from 12 March 2014)
Caspar von Hauenschild
(until 12 September 2013)
Stephan Holzinger
(from 20 November 2013)
Detlef Klimpe
Dr. Heinz Korte
Michael Mendel
Georg Schulze-Ziehaus
(from 3 July 2013)

ANTI-CORRUPTION COMMITTEE

(dissolved as of 6 November 2013)

Caspar von Hauenschild
Chairman
(until 12 September 2013)
Bettina Böttcher
Helmut Bühner
Werner Prange

COMMITTEE FOR COMPLIANCE AND COMMUNICATION

Stephan Holzinger
Chairman
(from 6 November 2013)
Bettina Böttcher
(from 6 November 2013)
Helmut Bühner
(from 6 November 2013)
Dr. Katrin Vernau
(from 12 March 2014)

MEDICAL INNOVATION AND QUALITY COMMITTEE

Eugen Münch
Chairman
Prof. Dr. Gerhard Ehninger
Prof. Dr. Dr. sc. (Harvard)
Karl W. Lauterbach
(until 4 June 2013)
Prof. Dr. Jan Schmitt
Georg Schulze-Ziehaus

NOMINATION COMMITTEE

Eugen Münch
Chairman
Dr. Brigitte Mohn
Wolfgang Mündel